ReposiTrak Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Für ReposiTrak wird ein Gewinn- und Umsatzwachstum von 14.1% bzw. 9.2% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 12% pro Jahr steigen soll.
Wichtige Informationen
14.1%
Wachstumsrate der Gewinne
12.01%
EPS-Wachstumsrate
| Software Gewinnwachstum | 20.4% |
| Wachstumsrate der Einnahmen | 9.2% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 15 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 24
TRAK: Expanding Food Traceability Adoption Will Support Future Upside Potential
Analysts kept their fair value estimate for ReposiTrak steady at $16.00, with only minor adjustments to inputs such as the discount rate and future P/E. These changes fine tune their price target view rather than reshape it.Seeking Alpha • Jun 20
ReposiTrak: Walmart And Kroger May Prove The Bears Wrong
Summary ReposiTrak earns a buy rating, targeting $10.2/share by FY 2027, implying 11% upside after a sharp recent pullback. TRAK’s fundamentals remain solid, with profitability and operating leverage improving despite flat Q3 revenue due to FSMA compliance deadline timing shifts. Demand for TRAK’s traceability solutions appears robust, supported by retailer adoption and industry trends beyond regulatory requirements. Risks include slower-than-expected traceability adoption, but TRAK’s scalable SaaS model and regulatory tailwinds underpin an attractive risk-reward profile. Read the full article on Seeking AlphaNarrativ-Update • Jun 03
TRAK: Expanding Traceability And Compliance Adoption Will Support Future Upside Potential
Analysts have adjusted their price target on ReposiTrak to $16.00. The update reflects refreshed assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple.Narrativ-Update • May 05
TRAK: Expanding Food Traceability Adoption And Compliance Wins Will Drive Upside
Analysts have kept their ReposiTrak price target effectively unchanged at approximately $16.00, reflecting only very small tweaks in inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the stock. What's in the News A wholesale grocery cooperative in the Southern United States became the first wholesaler to reach full supplier to store traceability using ReposiTrak’s Touchless Traceability solution, achieving FSMA 204 compliance without case-level scanning or changes to distribution center workflows (Key Developments).Narrativ-Update • Apr 19
TRAK: Expanding Traceability Network Adoption Will Support Future Upside
Analysts held ReposiTrak's fair value estimate at $16.00 per share while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the stock's risk and earnings profile. What's in the News ReposiTrak reported that eighteen fresh fruit and vegetable companies have joined the queue for the ReposiTrak Traceability Network to prepare for FDA Key Data Element sharing across their supply chains, covering a wide range of growers and distributors across the United States (Key Developments).Narrativ-Update • Apr 04
TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have maintained their $16.00 price target on ReposiTrak, linking this steady view to only slight adjustments in discount rate and future P/E assumptions rather than any change in projected growth or profitability. What's in the News ReposiTrak and SPAR Group, Inc.Narrativ-Update • Mar 21
TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have reaffirmed a $16.00 price target for ReposiTrak, citing only minimal tweaks to underlying assumptions such as discount rate, revenue growth, profit margin and future P/E, which together leave their overall valuation view effectively unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability is reported as the first to achieve end to end traceability under FDA FSMA Section 204, with hundreds of thousands of Key Data Element records generated across shipments, and several more corporate customers nearing similar go live milestones (Key Developments).Narrativ-Update • Mar 06
TRAK: Expanding Traceability Network And Share Buybacks Will Support Future Upside
Analysts have modestly reduced their price target on ReposiTrak to reflect a slightly lower future P/E assumption of 36.44x, while keeping key fair value and growth inputs broadly unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability has achieved end to end FSMA 204 traceability, generating hundreds of thousands of FDA Key Data Element records without case level scanning, with three more corporate customers close to similar go live points (Key Developments).Narrativ-Update • Feb 19
TRAK: Traceability Network Adoption Will Support Higher Future Profitability
Analysts have reduced their price target on ReposiTrak from $29 to $16, citing updated assumptions in their models for slower revenue growth, a lower future P/E multiple, and a higher profit margin profile. What's in the News ReposiTrak reported completing a share repurchase program announced on May 9, 2019, buying back a total of 2,220,026 shares, or 11.63% of the company, for US$14.46 million, including 79,927 shares, or 0.44%, repurchased between October 1, 2025 and December 31, 2025 for US$1.1 million (Key Developments).Analyseartikel • Oct 01
Investors Will Want ReposiTrak's (NYSE:TRAK) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analyseartikel • Aug 02
Subdued Growth No Barrier To ReposiTrak, Inc.'s (NYSE:TRAK) Price
ReposiTrak, Inc.'s ( NYSE:TRAK ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong sell...Analyseartikel • May 27
ReposiTrak's (NYSE:TRAK) Performance Is Even Better Than Its Earnings Suggest
ReposiTrak, Inc. ( NYSE:TRAK ) just reported healthy earnings but the stock price didn't move much. Investors are...Analyseartikel • Apr 12
Earnings Not Telling The Story For ReposiTrak, Inc. (NYSE:TRAK)
With a price-to-earnings (or "P/E") ratio of 62.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...Analyseartikel • Nov 09
ReposiTrak, Inc. (NYSE:TRAK) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 71.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...
Neues Narrativ • Oct 07
Critical Focus On Traceability Solutions Powers Revenue Growth And Profitability Surge
Emphasis on enhancing traceability solutions and strategic revenue focus predicts significant growth, with aims to improve net margins and year-over-year growth.Seeking Alpha • Oct 06
Track And Trace, But Don't Race: Why ReposiTrak Might Be Overvalued
Summary ReposiTrak shows solid growth potential with traceability services and recurring revenue but is currently overvalued with a high P/E ratio of 62.09x. Despite strong financials and profitability, rising operational expenses and heavy FDA dependency pose significant risks. Expansion into adjacent markets and AI-driven operational efficiencies are promising, but traceability revenue remains a small portion of the business. Given the speculative nature and high valuation, I recommend holding off on investing in ReposiTrak at this price. Read the full article on Seeking AlphaAnalyseartikel • Jul 24
ReposiTrak, Inc.'s (NYSE:TRAK) P/E Is Still On The Mark Following 28% Share Price Bounce
ReposiTrak, Inc. ( NYSE:TRAK ) shareholders have had their patience rewarded with a 28% share price jump in the last...Analyseartikel • Mar 23
ReposiTrak (NYSE:TRAK) Has More To Do To Multiply In Value Going Forward
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...Analyseartikel • Feb 28
Why Investors Shouldn't Be Surprised By ReposiTrak, Inc.'s (NYSE:TRAK) 28% Share Price Surge
Despite an already strong run, ReposiTrak, Inc. ( NYSE:TRAK ) shares have been powering on, with a gain of 28% in the...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 6/30/2028 | 29 | 10 | 10 | 10 | 1 |
| 6/30/2027 | 26 | 8 | 9 | 9 | 1 |
| 6/30/2026 | 24 | 7 | 11 | 11 | 1 |
| 3/31/2026 | 23 | 7 | 7 | 8 | N/A |
| 12/31/2025 | 24 | 7 | 7 | 7 | N/A |
| 9/30/2025 | 23 | 7 | 8 | 8 | N/A |
| 6/30/2025 | 23 | 7 | 8 | 8 | N/A |
| 3/31/2025 | 22 | 6 | 9 | 9 | N/A |
| 12/31/2024 | 21 | 6 | 10 | 10 | N/A |
| 9/30/2024 | 21 | 6 | 7 | 7 | N/A |
| 6/30/2024 | 20 | 5 | 7 | 7 | N/A |
| 3/31/2024 | 20 | 5 | 7 | 7 | N/A |
| 12/31/2023 | 20 | 5 | 7 | 8 | N/A |
| 9/30/2023 | 19 | 5 | 8 | 9 | N/A |
| 6/30/2023 | 19 | 5 | 8 | 9 | N/A |
| 3/31/2023 | 19 | 5 | 8 | 9 | N/A |
| 12/31/2022 | 19 | 4 | 6 | 6 | N/A |
| 9/30/2022 | 18 | 4 | 7 | 7 | N/A |
| 6/30/2022 | 18 | 3 | 6 | 6 | N/A |
| 3/31/2022 | 18 | 3 | 6 | 6 | N/A |
| 12/31/2021 | 20 | 3 | 4 | 5 | N/A |
| 9/30/2021 | 20 | 4 | 5 | 5 | N/A |
| 6/30/2021 | 21 | 4 | 5 | 5 | N/A |
| 3/31/2021 | 22 | 3 | 5 | 5 | N/A |
| 12/31/2020 | 21 | 2 | 5 | 5 | N/A |
| 9/30/2020 | 20 | 1 | 4 | 5 | N/A |
| 6/30/2020 | 20 | 1 | 4 | 4 | N/A |
| 3/31/2020 | 19 | 1 | 1 | 3 | N/A |
| 12/31/2019 | 19 | 2 | N/A | 5 | N/A |
| 9/30/2019 | 20 | 3 | N/A | 4 | N/A |
| 6/30/2019 | 21 | 3 | N/A | 5 | N/A |
| 3/31/2019 | 23 | 4 | N/A | 4 | N/A |
| 12/31/2018 | 23 | 4 | N/A | 3 | N/A |
| 9/30/2018 | 23 | 3 | N/A | 3 | N/A |
| 6/30/2018 | 22 | 3 | N/A | 2 | N/A |
| 3/31/2018 | 21 | 2 | N/A | 2 | N/A |
| 12/31/2017 | 20 | 3 | N/A | 3 | N/A |
| 9/30/2017 | 19 | 3 | N/A | 3 | N/A |
| 6/30/2017 | 19 | 3 | N/A | 2 | N/A |
| 3/31/2017 | 18 | 3 | N/A | 2 | N/A |
| 12/31/2016 | 16 | 2 | N/A | 1 | N/A |
| 9/30/2016 | 15 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 14 | 0 | N/A | 1 | N/A |
| 3/31/2016 | 14 | -3 | N/A | 1 | N/A |
| 12/31/2015 | 13 | -6 | N/A | 1 | N/A |
| 9/30/2015 | 13 | -7 | N/A | 1 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: TRAKDas prognostizierte Gewinnwachstum (14.1% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: TRAKDie Erträge des Unternehmens (14.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (18.2% pro Jahr).
Hohe Wachstumserträge: TRAKDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: TRAKDie Einnahmen des Unternehmens (9.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13% pro Jahr).
Hohe Wachstumseinnahmen: TRAKDie Einnahmen des Unternehmens (9.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TRAK in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/12 12:49 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
ReposiTrak, Inc. wird von 4 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Thomas Forte | D.A. Davidson & Co. |
| Ananda Baruah | Loop Capital Markets |
| Thomas Forte | Maxim Group |